JP4795688B2 - サンプル中の化合物を同定する方法および装置 - Google Patents
サンプル中の化合物を同定する方法および装置 Download PDFInfo
- Publication number
- JP4795688B2 JP4795688B2 JP2004543692A JP2004543692A JP4795688B2 JP 4795688 B2 JP4795688 B2 JP 4795688B2 JP 2004543692 A JP2004543692 A JP 2004543692A JP 2004543692 A JP2004543692 A JP 2004543692A JP 4795688 B2 JP4795688 B2 JP 4795688B2
- Authority
- JP
- Japan
- Prior art keywords
- values
- mass
- retention time
- value
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims description 80
- 238000000034 method Methods 0.000 title claims description 37
- 230000014759 maintenance of location Effects 0.000 claims description 62
- 238000004458 analytical method Methods 0.000 claims description 31
- 108010026552 Proteome Proteins 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 20
- 238000004587 chromatography analysis Methods 0.000 claims description 16
- 238000004949 mass spectrometry Methods 0.000 claims description 9
- 239000002207 metabolite Substances 0.000 claims description 9
- 238000000668 atmospheric pressure chemical ionisation mass spectrometry Methods 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 8
- 238000004811 liquid chromatography Methods 0.000 claims description 8
- 238000005070 sampling Methods 0.000 claims description 6
- 238000002366 time-of-flight method Methods 0.000 claims description 5
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 claims description 4
- 238000005481 NMR spectroscopy Methods 0.000 claims description 4
- 238000002451 electron ionisation mass spectrometry Methods 0.000 claims description 4
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 claims description 4
- 238000002101 electrospray ionisation tandem mass spectrometry Methods 0.000 claims description 4
- 230000007717 exclusion Effects 0.000 claims description 4
- 238000004817 gas chromatography Methods 0.000 claims description 4
- 238000005342 ion exchange Methods 0.000 claims description 4
- 238000002798 spectrophotometry method Methods 0.000 claims description 4
- 238000004808 supercritical fluid chromatography Methods 0.000 claims description 4
- 238000001819 mass spectrum Methods 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 238000013375 chromatographic separation Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000000523 sample Substances 0.000 description 40
- 238000010586 diagram Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000000513 principal component analysis Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000002359 drug metabolite Substances 0.000 description 1
- 238000012948 formulation analysis Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/78—Detectors specially adapted therefor using more than one detector
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/74—Optical detectors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
図1は本発明の特徴を具体化する装置を示す図である。
図2a、図2b、図2c、図2d、図2e、図2fおよび図2gは、本発明の方法および装置の特徴を示す図である。
図3は本発明の特徴を示す質量イオン化を示す図である。
Claims (20)
- 期間内に採取された複数のサンプルから得られた、メタボノーム、プロテオーム、およびゲノム成分からなる群から選択される二種以上の成分の、関連づけをするための方法であって、
a)前記複数のサンプルのうちの各サンプルをクロマトグラフィーによって、各々が1種または複数の化合物に関連する保持時間範囲により定義される複数のアリコートに分離して、前記化合物の保持時間値を得るステップと、
b)前記アリコートの各々について、前記保持時間範囲内の1種または複数の前記化合物に関連する1つまたは複数の質量値を有する質量分析を得て、各前記化合物の質量値を得るステップと、
c)各アリコートを、核磁気共鳴、FT−IR、UV/VIS分光光度法、蛍光および化学発光からなる群から選択される少なくとも1つのさらなる方式の分析に供して、前記化合物の各々についてさらなる分析値を得て、前記サンプル中の前記1種または複数の化合物を複数の前記保持時間値、複数の前記質量値、および前記さらなる分析値により関連づけて、経時的な、前記複数のサンプルのうちの異なるサンプルからの値の比較を容易にするステップと、
d)複数の前記保持時間値、複数の前記質量値、前記さらなる分析値、および異なるサンプリング時間における前記サンプル中の前記化合物の経時的濃度変化を得るステップと、
e)複数の前記保持時間値、複数の前記質量値、前記さらなる分析値、および或るサンプリング時間における前記サンプル中の前記化合物の前記経時的濃度変化を、前記サンプリング時間に関連づけられた複数の前記保持時間値によりリンクされた各サンプルのメタボノーム、プロテオーム、およびゲノム成分からなる群から選択される一種以上の成分に、関連づけをするステップと、
f)複数の前記保持時間値にリンクされた前記メタボノーム、プロテオーム、およびゲノム成分のうち二種以上から選択された二種以上の成分を比較して、前記成分中の変化を決定するステップと
を含むことを特徴とする、サンプル中の1種または複数の化合物を同定する方法。 - 少なくとも1つの方式の分析が前記複数のサンプル中の濃度または相対濃度に関係する値をもたらす請求項1に記載の方法。
- 前記複数のサンプルを経時的に採取し、前記1種または複数の化合物が質量および保持時間値により同定され、経時的な濃度の変化によりさらに同定される請求項1に記載の方法。
- 前記1種または複数の化合物を同様な値のデータベースと比較して、前記化合物の推定上の同一性を確定する請求項1に記載の方法。
- 前記クロマトグラフィーが液体クロマトグラフィー、超臨界流体クロマトグラフィーおよびガスクロマトグラフィーからなる群から選択される請求項1に記載の方法。
- 前記液体クロマトグラフィーがサイズ排除、イオン交換、逆相および順相からなる群から選択される請求項5に記載の方法。
- 前記質量分析がMALD−TOF、EI−MS、ESI−MSおよびESI−MS/MS、APCI−MSおよびAPCI−MS/MS、光イオン化MSおよびMS/MSからなる群から選択される請求項1に記載の方法。
- 前記複数のサンプルが、薬物を投与した1人または複数の人の生体組織、血液、および尿由来のものである請求項1に記載の方法。
- 前記保持時間値、質量値および相対濃度により同定される前記複数の化合物のうちの少なくともひとつが前記薬物である請求項1に記載の方法。
- 前記薬物が代謝されて第1の代謝物を生成し、前記第1の代謝物が前記薬物が代謝されるときに経時的に濃度の増加を示す請求項9に記載の方法。
- 期間内に採取される複数のサンプルから得られた、メタボノーム、プロテオーム、およびゲノム成分からなる群から選択される二種以上の成分の、関連づけをするための装置であって、
a)1種または複数の化合物の保持時間を得るために、クロマトグラフィーにより、サンプル中の1種または複数の化合物に関連する保持時間範囲別に、前記複数のサンプルのうちの各サンプルを、複数のアリコートに分離する手段と、
b)前記1種または複数の化合物に関連する前記1つまたは複数の質量値を生じさせる、前記アリコートの各々の質量分析を得るための手段と、
c)前記1種または複数の化合物に関連づけられたさらなる分析値を生じさせる、核磁気共鳴、FT−IR、UV/VIS分光光度法、蛍光および化学発光からなる群から選択される少なくとも1つのさらなる方式の分析に各アリコートを供する手段と、
d)前記保持時間の値、前記質量分析の値、前記さらなる分析値、および異なるサンプリング時間における前記サンプル中の前記化合物の経時的濃度変化を得るための手段と、
e)経時的に、異なるサンプルからの前記複数の値を比較することを促進するために、前記化合物の前記保持時間値を前記質量値および前記1つまたは複数のさらなる分析値と関連させるためのコンピュータ手段と、
f)複数の前記保持時間の値、複数の前記質量分析の値、前記さらなる分析値、および或るサンプリング時間における前記サンプル中の前記化合物の前記経時的濃度変化を、前記サンプリング時間に関連づけられた複数の前記保持時間の値によりリンクされた各サンプルのメタボノーム、プロテオーム、およびゲノム成分からなる群から選択される一種以上の成分に、関連づけをするための手段と、
g)複数の前記保持時間値にリンクされた前記メタボノーム、プロテオーム、およびゲノム成分のうち二種以上から選択された二種以上の成分を比較して、前記成分中の変化を決定するための手段と
を含む、装置。 - 前記複数のサンプルをある方式の分析に供する少なくとも1つの手段が前記サンプル中の濃度または相対濃度に関連させることができる値を生じさせる請求項11に記載の装置。
- 前記装置が経時的に前記複数のサンプルを受け、前記質量値および保持時間値により同定される1種または複数の化合物が経時的な濃度の変化によりさらに同定される請求項11に記載の装置。
- 前記コンピュータ手段が前記1種または複数の化合物を同様な値のデータベースと比較して、前記複数の化合物の推定上の同一性を確定する請求項11に記載の装置。
- 前記クロマトグラフィーが液体クロマトグラフィー、超臨界流体クロマトグラフィーおよびガスクロマトグラフィーからなる群から選択される請求項11に記載の装置。
- 前記液体クロマトグラフィーがサイズ排除、イオン交換、逆相および順相からなる群から選択される請求項11に記載の装置。
- 前記質量分析がMALD−TOF、EI−MS、ESI−MSおよびESI−MS/MS、APCI−MSおよびAPCI−MS/MS、光イオン化MSおよびMS/MSからなる群から選択される請求項11に記載の装置。
- 前記装置が、前記サンプルを薬物を投与した1人または複数の人の生体組織、血液、および尿から誘導するための、サンプル調製手段を含む、請求項11に記載の装置。
- 保持時間、質量スペクトルおよび相対濃度を用いて、前記コンピュータ手段によって同定される少なくとも1つの化合物が前記薬物である請求項11に記載の装置。
- 前記薬物が代謝されて第1の代謝物を生成し、前記第1の代謝物が前記薬物が代謝されるときに経時的に濃度の増加を示す請求項19に記載の装置。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41736602P | 2002-10-09 | 2002-10-09 | |
US60/417,366 | 2002-10-09 | ||
US42985102P | 2002-11-27 | 2002-11-27 | |
US60/429,851 | 2002-11-27 | ||
PCT/US2003/032211 WO2004034049A1 (en) | 2002-10-09 | 2003-10-09 | Methods and apparatus for identifying compounds in a sample |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006502414A JP2006502414A (ja) | 2006-01-19 |
JP4795688B2 true JP4795688B2 (ja) | 2011-10-19 |
Family
ID=32096194
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004543692A Expired - Fee Related JP4795688B2 (ja) | 2002-10-09 | 2003-10-09 | サンプル中の化合物を同定する方法および装置 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20050233464A1 (ja) |
JP (1) | JP4795688B2 (ja) |
AU (1) | AU2003284060A1 (ja) |
CA (1) | CA2501861C (ja) |
DE (1) | DE10393475B4 (ja) |
GB (1) | GB2409038B (ja) |
WO (1) | WO2004034049A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005536714A (ja) * | 2001-11-13 | 2005-12-02 | カプリオン ファーマシューティカルズ インコーポレーティッド | 質量強度プロファイリングシステムおよびその使用法 |
EP1586107A2 (en) * | 2002-11-22 | 2005-10-19 | Caprion Pharmaceuticals, Inc. | Constellation mapping and uses thereof |
JP4818270B2 (ja) * | 2004-05-20 | 2011-11-16 | ウオーターズ・テクノロジーズ・コーポレイシヨン | 選択されたイオンクロマトグラムを使用して先駆物質および断片イオンをグループ化するシステムおよび方法 |
CN1811408B (zh) * | 2005-01-28 | 2010-04-28 | 方向 | 内部光电离离子阱质量分析装置及其方法 |
GB201617460D0 (en) | 2016-10-14 | 2016-11-30 | Micromass Uk Limited | Combined gas chromatography vacuum ultra-violet detector with mass spectrometer or ion mobility spectrometer |
US11070249B2 (en) * | 2017-09-28 | 2021-07-20 | British Telecommunications Public Limited Company | Controlling communications in respect of local area networks |
WO2019072546A1 (en) | 2017-10-10 | 2019-04-18 | British Telecommunications Public Limited Company | IDENTIFICATION OF INTERFERING LINKS IN LOCAL NETWORKS |
WO2020194955A1 (ja) * | 2019-03-22 | 2020-10-01 | 株式会社島津製作所 | 試料測定装置および測定試料同定方法 |
JP7306090B2 (ja) * | 2019-06-17 | 2023-07-11 | 株式会社島津製作所 | 香気性化合物の分離方法及び超臨界流体クロマトグラフ |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4863873A (en) * | 1980-01-14 | 1989-09-05 | Esa, Inc. | Method for biological testing and/or developing pharmaceuticals for treatment of disorders |
US5185267A (en) * | 1988-10-28 | 1993-02-09 | The Board Of Governors Of Wayne State University | Method for detecting maternally transferred drug metabolites in newborn infants |
US5326708A (en) * | 1992-02-28 | 1994-07-05 | Lewis Douglas E | Forensically acceptable determinations of gestational fetal exposure to drugs and other chemical agents |
WO2001084143A1 (en) * | 2000-04-13 | 2001-11-08 | Thermo Finnigan Llc | Proteomic analysis by parallel mass spectrometry |
WO2001096895A1 (en) * | 2000-06-14 | 2001-12-20 | Amersham Plc | Method for investigating the fate of a test compound or the stateof a biological system by means of nmr of hyperpolarised nmr active nuclei |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4511659A (en) * | 1983-03-04 | 1985-04-16 | Esa, Inc. | Liquid chromatograph with electrochemical detector and method |
US5327708A (en) * | 1991-02-28 | 1994-07-12 | Gerrish Steven R | Crop testing and evaluation system |
DE4231085A1 (de) * | 1992-09-12 | 1994-03-17 | Desitin Arzneimittel Gmbh | VPA-analoge Antiepileptika |
US6210918B1 (en) * | 1992-10-09 | 2001-04-03 | The Regents Of The University Of California | Non-invasive method for detection, diagnosis or prediction of term or pre-term labor |
US5783397A (en) * | 1995-12-11 | 1998-07-21 | Northeastern University | Screening natural samples for new therapeutic compounds using capillary electrophoresis |
DE1066523T1 (de) * | 1998-03-27 | 2001-09-20 | Microgenics Corp | Kontrollbestimmungsmethoden für drogen bestehend aus kleinen molekülen |
AU3515100A (en) * | 1999-03-09 | 2000-09-28 | Purdue University | Improved desorption/ionization of analytes from porous light-absorbing semiconductor |
EP2293056A3 (en) * | 1999-04-20 | 2011-06-29 | Target Discovery, Inc. | A method for analysing a metabolic pathway |
MXPA02007664A (es) * | 2000-02-08 | 2004-08-23 | Univ Michigan | Separacion y representacion de proteinas. |
-
2003
- 2003-10-09 AU AU2003284060A patent/AU2003284060A1/en not_active Abandoned
- 2003-10-09 GB GB0507026A patent/GB2409038B/en not_active Expired - Fee Related
- 2003-10-09 DE DE10393475.8T patent/DE10393475B4/de not_active Expired - Fee Related
- 2003-10-09 WO PCT/US2003/032211 patent/WO2004034049A1/en active Application Filing
- 2003-10-09 CA CA2501861A patent/CA2501861C/en not_active Expired - Fee Related
- 2003-10-09 JP JP2004543692A patent/JP4795688B2/ja not_active Expired - Fee Related
-
2005
- 2005-04-06 US US11/099,891 patent/US20050233464A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4863873A (en) * | 1980-01-14 | 1989-09-05 | Esa, Inc. | Method for biological testing and/or developing pharmaceuticals for treatment of disorders |
US5185267A (en) * | 1988-10-28 | 1993-02-09 | The Board Of Governors Of Wayne State University | Method for detecting maternally transferred drug metabolites in newborn infants |
US5326708A (en) * | 1992-02-28 | 1994-07-05 | Lewis Douglas E | Forensically acceptable determinations of gestational fetal exposure to drugs and other chemical agents |
WO2001084143A1 (en) * | 2000-04-13 | 2001-11-08 | Thermo Finnigan Llc | Proteomic analysis by parallel mass spectrometry |
WO2001096895A1 (en) * | 2000-06-14 | 2001-12-20 | Amersham Plc | Method for investigating the fate of a test compound or the stateof a biological system by means of nmr of hyperpolarised nmr active nuclei |
Also Published As
Publication number | Publication date |
---|---|
AU2003284060A1 (en) | 2004-05-04 |
DE10393475T5 (de) | 2005-08-25 |
GB2409038B (en) | 2006-04-05 |
CA2501861C (en) | 2012-03-20 |
WO2004034049A1 (en) | 2004-04-22 |
CA2501861A1 (en) | 2004-04-22 |
GB2409038A (en) | 2005-06-15 |
DE10393475B4 (de) | 2014-09-25 |
JP2006502414A (ja) | 2006-01-19 |
GB0507026D0 (en) | 2005-05-11 |
US20050233464A1 (en) | 2005-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nalbantoglu | Metabolomics: basic principles and strategies | |
Korfmacher et al. | Cassette‐accelerated rapid rat screen: a systematic procedure for the dosing and liquid chromatography/atmospheric pressure ionization tandem mass spectrometric analysis of new chemical entities as part of new drug discovery | |
CN104165937B (zh) | 一种高效液相-高分辨率飞行时间串联质谱法检测血液中降血糖以及降血压药物的方法 | |
Adamowicz et al. | Simultaneous screening for and determination of 128 date-rape drugs in urine by gas chromatography–electron ionization-mass spectrometry | |
Wu et al. | Role of liquid chromatography–high-resolution mass spectrometry (LC-HR/MS) in clinical toxicology | |
Montesano et al. | Determination of illicit drugs and metabolites in oral fluid by microextraction on packed sorbent coupled with LC-MS/MS | |
Apollonio et al. | A demonstration of the use of ultra-performance liquid chromatography–mass spectrometry [UPLC/MS] in the determination of amphetamine-type substances and ketamine for forensic and toxicological analysis | |
Wang et al. | Analysis of six synthetic adulterants in herbal weight-reducing dietary supplements by LC electrospray ionization-MS | |
US20050233464A1 (en) | Methods and apparatus for identifying compounds in a sample | |
Pelander et al. | Screening for basic drugs in hair of drug addicts by liquid chromatography/time-of-flight mass spectrometry | |
Amaratunga et al. | Quantitative measurement of synthetic cathinones in oral fluid | |
US20050101023A1 (en) | Methods for diagnosing urinary tract and prostatic disorders | |
Liu et al. | Direct injection LC–MS-MS analysis of opiates, methamphetamine, buprenorphine, methadone and their metabolites in oral fluid from substitution therapy patients | |
Kuwayama et al. | Strong evidence of drug-facilitated crimes by hair analysis using LC–MS/MS after micro-segmentation | |
Li et al. | An approach to develop binary chromatographic fingerprints of the total alkaloids from Caulophyllum robustum by high performance liquid chromatography/diode array detector and gas chromatography/mass spectrometry | |
Garcia et al. | Analysis of β‐agonists by HPLC/ESI‐MSn in horse doping control | |
Wang et al. | Use of SPE and LC/TIS/MS/MS for rapid detection and quantitation of ketamine and its metabolite, norketamine, in urine | |
Scholz et al. | A comprehensive multi-analyte method for hair analysis: substance-specific quantification ranges and tool for task-oriented data evaluation | |
Wu et al. | High-resolution mass spectrometry for untargeted drug screening | |
Borg et al. | Chiral analysis of methamphetamine in oral fluid samples: a method to distinguish licit from illicit drug use | |
Zou et al. | Rapid simultaneous determination of gut microbial phenylalanine, tyrosine, and tryptophan metabolites in rat serum, urine, and faeces using LC–MS/MS and its application to a type 2 diabetes mellitus study | |
Domagalska et al. | Fatal N-ethylhexedrone intoxication | |
Humbert et al. | Drugs involved in drug-facilitated crimes (DFC): analytical aspects: 1—blood and urine | |
Abdel‐Hamid | Determination of sildenafil, tadalafil, and vardenafil in tablets and adulterated herbal products by ESI‐MS‐MS | |
Pršo et al. | A high‐throughput LC–MS/MS method for simultaneous determination of isoniazid, ethambutol and pyrazinamide in human plasma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061002 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20090717 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20091019 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091124 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100217 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100224 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100524 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101207 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110301 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110308 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110606 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110719 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110728 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4795688 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140805 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |